Floatz logo

Polyiclc

Refractory Anemia

Roswell Park Cancer InstitutePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Refractory Anemia cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BBB
Monomethyl Fumarate
Masonic Cancer Center, University of Minnesota
Phase 2BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BB
FILGRASTIM
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BB

View all 37 →

Same molecule, other indications

Polyiclc is also rated in:

Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
B
Indicative ·
63 / 100
View asset →
melanomaDormant
B
Indicative ·
63 / 100
View asset →
ocular melanomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →